JP2022528024A5 - - Google Patents
Info
- Publication number
- JP2022528024A5 JP2022528024A5 JP2021525181A JP2021525181A JP2022528024A5 JP 2022528024 A5 JP2022528024 A5 JP 2022528024A5 JP 2021525181 A JP2021525181 A JP 2021525181A JP 2021525181 A JP2021525181 A JP 2021525181A JP 2022528024 A5 JP2022528024 A5 JP 2022528024A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- tumor
- cells
- binding domain
- tag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025072427A JP2025129148A (ja) | 2018-10-30 | 2025-04-24 | Carを発現する免疫細胞に抗原提示細胞を係合させるための二重特異性ポリペプチド及びそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018904117A AU2018904117A0 (en) | 2018-10-30 | Polypeptides and uses thereof | |
| AU2018904117 | 2018-10-30 | ||
| AU2019903255A AU2019903255A0 (en) | 2019-09-04 | Polypeptides and uses thereof | |
| AU2019903255 | 2019-09-04 | ||
| PCT/AU2019/051189 WO2020087116A1 (en) | 2018-10-30 | 2019-10-29 | Bispecific polypeptides for engagement of car expressing immune cells with antigen presenting cells and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025072427A Division JP2025129148A (ja) | 2018-10-30 | 2025-04-24 | Carを発現する免疫細胞に抗原提示細胞を係合させるための二重特異性ポリペプチド及びそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022528024A JP2022528024A (ja) | 2022-06-08 |
| JP2022528024A5 true JP2022528024A5 (cg-RX-API-DMAC7.html) | 2022-11-10 |
| JP7674243B2 JP7674243B2 (ja) | 2025-05-09 |
Family
ID=70461795
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525181A Active JP7674243B2 (ja) | 2018-10-30 | 2019-10-29 | Carを発現する免疫細胞に抗原提示細胞を係合させるための二重特異性ポリペプチド及びそれらの使用 |
| JP2025072427A Pending JP2025129148A (ja) | 2018-10-30 | 2025-04-24 | Carを発現する免疫細胞に抗原提示細胞を係合させるための二重特異性ポリペプチド及びそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025072427A Pending JP2025129148A (ja) | 2018-10-30 | 2025-04-24 | Carを発現する免疫細胞に抗原提示細胞を係合させるための二重特異性ポリペプチド及びそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11866504B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3877417A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7674243B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102961312B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113195535A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019370618C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3117079A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202104180WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020087116A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230364234A1 (en) * | 2020-03-06 | 2023-11-16 | Albert Einstein College Of Medicine | Compositions and methods for chimeric antigen receptor (car)-modified cell modulation |
| CN116390941A (zh) * | 2020-07-16 | 2023-07-04 | 南京传奇生物科技有限公司 | 多特异性嵌合抗原受体及其用途 |
| JP7846667B2 (ja) | 2020-07-16 | 2026-04-15 | レジェンド バイオテック アイルランド リミテッド | Cd20結合分子及びその使用 |
| CA3262796A1 (en) * | 2022-09-20 | 2024-03-28 | Currus Biologics Pty Ltd | Bispecific Polypeptides and Their Uses |
| EP4590710A1 (en) * | 2022-09-20 | 2025-07-30 | Currus Biologics Pty Ltd | A method of rescuing exhausted immune cells |
| AU2023347073A1 (en) * | 2022-09-20 | 2025-01-02 | Currus Biologics Pty Ltd | Anti-flag antibodies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2688035T3 (es) * | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| CN104829730A (zh) * | 2015-04-14 | 2015-08-12 | 苏静 | 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用 |
| EP3295171A1 (en) | 2015-05-12 | 2018-03-21 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and kits for labeling, detection and isolation of foxp3+ regulatory t cells, isolated population of foxp3+ regulatory t cells thus obtained and uses thereof |
| WO2017167350A1 (en) * | 2016-03-30 | 2017-10-05 | Horst Lindhofer | Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract |
| WO2017177337A1 (en) | 2016-04-15 | 2017-10-19 | Zymeworks Inc. | Multi-specific antigen-binding constructs targeting immunotherapeutics |
| BR112019000512A2 (pt) * | 2016-07-14 | 2019-04-24 | Genmab A/S | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit |
| CA3050614A1 (en) * | 2017-03-17 | 2018-09-20 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
| CN107417792B (zh) | 2017-08-29 | 2020-07-03 | 天津医科大学总医院 | 抗cd40-her2双特异性单链抗体及其在制备抗肿瘤药物中的应用 |
| AU2019315440B2 (en) * | 2018-07-30 | 2025-03-13 | Angeles Therapeutics, Inc. | Improving the efficacy and safety of adoptive cellular therapies |
-
2019
- 2019-10-29 SG SG11202104180WA patent/SG11202104180WA/en unknown
- 2019-10-29 CN CN201980075175.XA patent/CN113195535A/zh active Pending
- 2019-10-29 AU AU2019370618A patent/AU2019370618C1/en active Active
- 2019-10-29 KR KR1020217016400A patent/KR102961312B1/ko active Active
- 2019-10-29 CA CA3117079A patent/CA3117079A1/en active Pending
- 2019-10-29 WO PCT/AU2019/051189 patent/WO2020087116A1/en not_active Ceased
- 2019-10-29 US US17/289,997 patent/US11866504B2/en active Active
- 2019-10-29 EP EP19879319.2A patent/EP3877417A4/en active Pending
- 2019-10-29 JP JP2021525181A patent/JP7674243B2/ja active Active
-
2022
- 2022-11-04 AU AU2022263573A patent/AU2022263573B2/en active Active
-
2023
- 2023-11-13 US US18/507,157 patent/US20240150482A1/en active Pending
-
2025
- 2025-04-24 JP JP2025072427A patent/JP2025129148A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Iwahori | Cytotoxic CD8+ lymphocytes in the tumor microenvironment | |
| US20240325450A1 (en) | Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same | |
| Yu et al. | Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma | |
| JP2021523110A (ja) | 遺伝子発現のためのナノ粒子及びその使用 | |
| CA3162930A1 (en) | Recombinant polypeptides for programming extracellular vesicles | |
| US12491201B2 (en) | Maximizing T-cell memory and compositions and methods therefor | |
| JP2018509163A5 (cg-RX-API-DMAC7.html) | ||
| JP2017514471A5 (cg-RX-API-DMAC7.html) | ||
| JP2024515319A5 (cg-RX-API-DMAC7.html) | ||
| Ghorashian et al. | CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor | |
| Stefanidis et al. | Combining SiRPα decoy–coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells | |
| EP4242309A1 (en) | Chimeric antigen receptor | |
| EP4232566A1 (en) | Chimeric activation receptors | |
| JP2023503840A5 (cg-RX-API-DMAC7.html) | ||
| JP2022525927A5 (cg-RX-API-DMAC7.html) | ||
| CN120676960A (zh) | 开发增强car t细胞的功能和/或持久性的car衔接分子平台 | |
| Jiang et al. | Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors | |
| Kucharczyk et al. | Adoptive T-cell therapy in sarcomas | |
| JP2020537517A5 (cg-RX-API-DMAC7.html) | ||
| Fujii et al. | NKT-Licensed In Vivo Dendritic Cell− Based Immunotherapy as Cellular Immunodrugs for Cancer Treatment | |
| Kang et al. | Control of spontaneous ovarian tumors by CD8+ T cells through NKG2D-targeted delivery of antigenic peptide | |
| CN114437229B (zh) | 携带pd-1単链抗体且靶向egfr抗原的car t免疫细胞的制备及其用途 | |
| HK40090148A (en) | Nkt-cell subset for in vivo persistence and therapeutic activity and ppropagation of same | |
| KR20250089551A (ko) | 입양 세포 요법과 표적 면역사이토카인을 조합하여 이용한 암 치료 방법 | |
| HK40117726A (en) | Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same |